Published in Pharmacol Ther on February 01, 2010
The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors. Br J Pharmacol (2013) 5.74
Cannabinoid hyperemesis: a case series of 98 patients. Mayo Clin Proc (2012) 3.24
Blurred boundaries: the therapeutics and politics of medical marijuana. Mayo Clin Proc (2012) 1.79
Is lipid signaling through cannabinoid 2 receptors part of a protective system? Prog Lipid Res (2011) 1.60
Modulating the endocannabinoid system in human health and disease--successes and failures. FEBS J (2013) 1.59
Role of gut nutrient sensing in stimulating appetite and conditioning food preferences. Am J Physiol Regul Integr Comp Physiol (2012) 1.53
O-2050 facilitates noradrenaline release and increases the CB1 receptor inverse agonistic effect of rimonabant in the guinea pig hippocampus. Naunyn Schmiedebergs Arch Pharmacol (2014) 1.38
Endocannabinoid signal in the gut controls dietary fat intake. Proc Natl Acad Sci U S A (2011) 1.29
Stress and visceral pain: from animal models to clinical therapies. Exp Neurol (2011) 1.25
Endocannabinoid signaling at the periphery: 50 years after THC. Trends Pharmacol Sci (2015) 1.25
Inhibition of monoacylglycerol lipase attenuates nonsteroidal anti-inflammatory drug-induced gastric hemorrhages in mice. J Pharmacol Exp Ther (2011) 1.14
Brain-Gut Interactions in IBS. Front Pharmacol (2012) 1.10
Regulation of nausea and vomiting by cannabinoids and the endocannabinoid system. Eur J Pharmacol (2013) 1.08
The thrifty lipids: endocannabinoids and the neural control of energy conservation. Trends Neurosci (2012) 1.08
Endocannabinoid tone versus constitutive activity of cannabinoid receptors. Br J Pharmacol (2011) 1.05
Contributions of endocannabinoid signaling to psychiatric disorders in humans: genetic and biochemical evidence. Neuroscience (2011) 1.01
Cannabinoids alleviate experimentally induced intestinal inflammation by acting at central and peripheral receptors. PLoS One (2014) 0.95
Inhibitory effect of cannabichromene, a major non-psychotropic cannabinoid extracted from Cannabis sativa, on inflammation-induced hypermotility in mice. Br J Pharmacol (2012) 0.93
High tumour cannabinoid CB1 receptor immunoreactivity negatively impacts disease-specific survival in stage II microsatellite stable colorectal cancer. PLoS One (2011) 0.93
Experimental colitis in mice is attenuated by changes in the levels of endocannabinoid metabolites induced by selective inhibition of fatty acid amide hydrolase (FAAH). J Crohns Colitis (2014) 0.92
Cannabinoid-Induced Hyperemesis: A Conundrum-From Clinical Recognition to Basic Science Mechanisms. Pharmaceuticals (Basel) (2010) 0.92
Endocannabinoids - at the crossroads between the gut microbiota and host metabolism. Nat Rev Endocrinol (2015) 0.92
Interplay between inflammation, immune system and neuronal pathways: effect on gastrointestinal motility. World J Gastroenterol (2010) 0.91
Small intestinal cannabinoid receptor changes following a single colonic insult with oil of mustard in mice. Front Pharmacol (2010) 0.90
Inhibiting fatty acid amide hydrolase normalizes endotoxin-induced enhanced gastrointestinal motility in mice. Br J Pharmacol (2012) 0.89
Somatostatin receptor 5 and cannabinoid receptor 1 activation inhibit secretion of glucose-dependent insulinotropic polypeptide from intestinal K cells in rodents. Diabetologia (2012) 0.89
Current and future drug targets in weight management. Pharm Res (2010) 0.88
Association of genetic variation in cannabinoid mechanisms and gastric motor functions and satiation in overweight and obesity. Neurogastroenterol Motil (2011) 0.87
Intestinal lipid-derived signals that sense dietary fat. J Clin Invest (2015) 0.85
β-Caryophyllene ameliorates cisplatin-induced nephrotoxicity in a cannabinoid 2 receptor-dependent manner. Free Radic Biol Med (2012) 0.85
Case of cannabinoid hyperemesis syndrome with long-term follow-up. World J Clin Cases (2014) 0.84
A new generation fatty acid amide hydrolase inhibitor protects against kainate-induced excitotoxicity. J Mol Neurosci (2010) 0.84
Role of enteric neurotransmission in host defense and protection of the gastrointestinal tract. Auton Neurosci (2013) 0.83
Evidence for the putative cannabinoid receptor (GPR55)-mediated inhibitory effects on intestinal contractility in mice. Pharmacology (2012) 0.83
Mid-ventricular variant takotsubo cardiomyopathy associated with Cannabinoid Hyperemesis Syndrome: a case report. Hawaii J Med Public Health (2014) 0.82
Gastroesophageal reflux symptoms not responding to proton pump inhibitor: GERD, NERD, NARD, esophageal hypersensitivity or dyspepsia? Can J Gastroenterol Hepatol (2014) 0.82
Stress regulates endocannabinoid-CB1 receptor signaling. Semin Immunol (2014) 0.82
Plasticity of mouse enteric synapses mediated through endocannabinoid and purinergic signaling. Neurogastroenterol Motil (2012) 0.82
Stimulation of incretin secreting cells. Ther Adv Endocrinol Metab (2016) 0.81
Cannabis finds its way into treatment of Crohn's disease. Pharmacology (2013) 0.81
The GPR55 antagonist CID16020046 protects against intestinal inflammation. Neurogastroenterol Motil (2015) 0.81
Inhibiting endocannabinoid biosynthesis: a novel approach to the treatment of constipation. Br J Pharmacol (2015) 0.80
Role of Cannabinoids in Gastrointestinal Mucosal Defense and Inflammation. Curr Neuropharmacol (2016) 0.80
Blockade of cannabinoid 1 receptor improves GLP-1R mediated insulin secretion in mice. Mol Cell Endocrinol (2015) 0.80
Monoglyceride lipase deficiency causes desensitization of intestinal cannabinoid receptor type 1 and increased colonic μ-opioid receptor sensitivity. Br J Pharmacol (2015) 0.79
Mechanisms of Broad-Spectrum Antiemetic Efficacy of Cannabinoids against Chemotherapy-Induced Acute and Delayed Vomiting. Pharmaceuticals (Basel) (2010) 0.79
Cannabinoids receptor type 2, CB2, expression correlates with human colon cancer progression and predicts patient survival. Oncoscience (2015) 0.79
Environment-related adaptive changes of gut commensal microbiota do not alter colonic toll-like receptors but modulate the local expression of sensory-related systems in rats. Microb Ecol (2013) 0.79
The Role of the Endocannabinoid System in the Brain-Gut Axis. Gastroenterology (2016) 0.78
AM841, a covalent cannabinoid ligand, powerfully slows gastrointestinal motility in normal and stressed mice in a peripherally restricted manner. Br J Pharmacol (2015) 0.78
Palmitoylethanolamide regulates development of intestinal radiation injury in a mast cell-dependent manner. Dig Dis Sci (2014) 0.78
The gastrointestinal tract - a central organ of cannabinoid signaling in health and disease. Neurogastroenterol Motil (2016) 0.77
Endocannabinoids in the Gut. Cannabis Cannabinoid Res (2016) 0.77
Acute Δ(9)-tetrahydrocannabinol blocks gastric hemorrhages induced by the nonsteroidal anti-inflammatory drug diclofenac sodium in mice. Eur J Pharmacol (2013) 0.77
Fatty acid amide hydrolase (FAAH) blockade ameliorates experimental colitis by altering microRNA expression and suppressing inflammation. Brain Behav Immun (2016) 0.76
[Efficacy, tolerability, and safety of cannabinoids in gastroenterology : A systematic review]. Schmerz (2016) 0.76
Cannabinoids for treating inflammatory bowel diseases: where are we and where do we go? Expert Rev Gastroenterol Hepatol (2017) 0.75
Anti-inflammatory effect of cannabinoid agonist WIN55, 212 on mouse experimental colitis is related to inhibition of p38MAPK. World J Gastroenterol (2016) 0.75
Response to Utomo et al. Am J Gastroenterol (2015) 0.75
Cannabinoid receptor type-1: breaking the dogmas. F1000Res (2016) 0.75
Abnormal cannabidiol attenuates experimental colitis in mice, promotes wound healing and inhibits neutrophil recruitment. J Inflamm (Lond) (2016) 0.75
Trisubstituted Sulfonamides: a New Chemotype for Development of Potent and Selective CB2 Receptor Inverse Agonists. ACS Med Chem Lett (2013) 0.75
Clinical Significance of Cannabinoid Receptors CB1 and CB2 Expression in Human Malignant and Benign Thyroid Lesions. Biomed Res Int (2015) 0.75
New pharmacological approaches against chronic bowel and bladder problems in paralytics. World J Crit Care Med (2016) 0.75
Involvement of Cannabinoid Signaling in Vincristine-Induced Gastrointestinal Dysmotility in the Rat. Front Pharmacol (2017) 0.75
Characterization of Dronabinol Usage in a Pediatric Oncology Population. J Pediatr Pharmacol Ther (2016) 0.75
RGS proteins as targets in the treatment of intestinal inflammation and visceral pain: New insights and future perspectives. Bioessays (2016) 0.75
Peripheral endocannabinoid signaling controls hyperphagia in western diet-induced obesity. Physiol Behav (2017) 0.75
Cannabimimetic phytochemicals in the diet - an evolutionary link to food selection and metabolic stress adaptation? Br J Pharmacol (2016) 0.75
G protein-coupled receptor GPR55 promotes colorectal cancer and has opposing effects to cannabinoid receptor 1. Int J Cancer (2017) 0.75
Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science (2005) 5.12
Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology (2004) 4.04
Activation of colonic mucosal 5-HT(4) receptors accelerates propulsive motility and inhibits visceral hypersensitivity. Gastroenterology (2012) 2.11
Role for protease activity in visceral pain in irritable bowel syndrome. J Clin Invest (2007) 2.09
Activation of neuronal P2X7 receptor-pannexin-1 mediates death of enteric neurons during colitis. Nat Med (2012) 2.08
Inflammatory neuropathies of the enteric nervous system. Gastroenterology (2004) 2.02
Gastric bypass increases energy expenditure in rats. Gastroenterology (2009) 1.79
Serotonin availability is increased in mucosa of guinea pigs with TNBS-induced colitis. Am J Physiol Gastrointest Liver Physiol (2003) 1.78
Enhanced excitability of myenteric AH neurones in the inflamed guinea-pig distal colon. J Physiol (2003) 1.65
Microglial activation and TNFalpha production mediate altered CNS excitability following peripheral inflammation. Proc Natl Acad Sci U S A (2008) 1.55
Purinergic neuron-to-glia signaling in the enteric nervous system. Gastroenterology (2009) 1.48
Novel functional roles for enteric glia in the gastrointestinal tract. Nat Rev Gastroenterol Hepatol (2012) 1.44
Activation of the cannabinoid 2 receptor (CB2) protects against experimental colitis. Inflamm Bowel Dis (2009) 1.35
Effects of cannabinoid receptor-2 activation on accelerated gastrointestinal transit in lipopolysaccharide-treated rats. Br J Pharmacol (2004) 1.33
Delta9-tetrahydrocannabinol selectively acts on CB1 receptors in specific regions of dorsal vagal complex to inhibit emesis in ferrets. Am J Physiol Gastrointest Liver Physiol (2003) 1.32
Should peripheral CB(1) cannabinoid receptors be selectively targeted for therapeutic gain? Trends Pharmacol Sci (2008) 1.30
Enteroendocrine cells and 5-HT availability are altered in mucosa of guinea pigs with TNBS ileitis. Am J Physiol Gastrointest Liver Physiol (2004) 1.29
Effects of gastrointestinal inflammation on enteroendocrine cells and enteric neural reflex circuits. Auton Neurosci (2006) 1.21
Cyclooxygenase-2 contributes to dysmotility and enhanced excitability of myenteric AH neurones in the inflamed guinea pig distal colon. J Physiol (2004) 1.20
Role of enteric glia in intestinal physiology: effects of the gliotoxin fluorocitrate on motor and secretory function. Am J Physiol Gastrointest Liver Physiol (2006) 1.19
Targeting endocannabinoid degradation protects against experimental colitis in mice: involvement of CB1 and CB2 receptors. J Mol Med (Berl) (2008) 1.19
The endocannabinoid system and gut-brain signalling. Curr Opin Pharmacol (2007) 1.17
Enteric neural pathways mediate the anti-inflammatory actions of glucagon-like peptide 2. Am J Physiol Gastrointest Liver Physiol (2007) 1.16
Inducible nitric oxide synthase from bone marrow-derived cells plays a critical role in regulating colonic inflammation. Gastroenterology (2007) 1.16
Synaptic facilitation and enhanced neuronal excitability in the submucosal plexus during experimental colitis in guinea-pig. J Physiol (2005) 1.15
A neutral CB1 receptor antagonist reduces weight gain in rat. Am J Physiol Regul Integr Comp Physiol (2007) 1.15
Dendritically released transmitters cooperate via autocrine and retrograde actions to inhibit afferent excitation in rat brain. J Physiol (2004) 1.13
Purinergic neuromuscular transmission is selectively attenuated in ulcerated regions of inflamed guinea pig distal colon. J Physiol (2010) 1.12
Cannabinoid (CB)1 receptor antagonist, AM 251, causes a sustained reduction of daily food intake in the rat. Physiol Behav (2004) 1.12
Cannabinoid CB2 receptors in the enteric nervous system modulate gastrointestinal contractility in lipopolysaccharide-treated rats. Am J Physiol Gastrointest Liver Physiol (2008) 1.10
Persistent alterations to enteric neural signaling in the guinea pig colon following the resolution of colitis. Am J Physiol Gastrointest Liver Physiol (2006) 1.09
Emerging roles for enteric glia in gastrointestinal disorders. J Clin Invest (2015) 1.08
Enteric glia are targets of the sympathetic innervation of the myenteric plexus in the guinea pig distal colon. J Neurosci (2010) 1.08
Cannabinoids in intestinal inflammation and cancer. Pharmacol Res (2009) 1.08
Synaptic plasticity in myenteric neurons of the guinea-pig distal colon: presynaptic mechanisms of inflammation-induced synaptic facilitation. J Physiol (2007) 1.08
Dextran sodium sulfate-induced colitis reveals nicotinic modulation of ion transport via iNOS-derived NO. Am J Physiol Gastrointest Liver Physiol (2004) 1.07
The atypical cannabinoid O-1602 protects against experimental colitis and inhibits neutrophil recruitment. Inflamm Bowel Dis (2010) 1.07
Ectonucleotidases in the digestive system: focus on NTPDase3 localization. Am J Physiol Gastrointest Liver Physiol (2011) 1.07
Nitric oxide regulation of colonic epithelial ion transport: a novel role for enteric glia in the myenteric plexus. J Physiol (2011) 1.06
Area postrema neurons are modulated by the adipocyte hormone adiponectin. J Neurosci (2006) 1.06
Inducible nitric oxide synthase (iNOS) in endotoxemia: chimeric mice reveal different cellular sources in various tissues. FASEB J (2002) 1.03
Cannabinoid CB(2) receptors in health and disease. Curr Med Chem (2010) 1.01
Ileitis alters neuronal and enteroendocrine signalling in guinea pig distal colon. Gut (2006) 1.01
Effects of PGE2 in guinea pig colonic myenteric ganglia. Am J Physiol Gastrointest Liver Physiol (2002) 1.01
Distribution of adrenergic receptors in the enteric nervous system of the guinea pig, mouse, and rat. J Comp Neurol (2006) 1.00
Consequences of Citrobacter rodentium infection on enteroendocrine cells and the enteric nervous system in the mouse colon. Cell Microbiol (2006) 0.98
Distribution and function of the cannabinoid-1 receptor in the modulation of ion transport in the guinea pig ileum: relationship to capsaicin-sensitive nerves. Am J Physiol Gastrointest Liver Physiol (2003) 0.96
Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone (SAB378), a peripherally restricted cannabinoid CB1/CB2 receptor agonist, inhibits gastrointestinal motility but has no effect on experimental colitis in mice. J Pharmacol Exp Ther (2010) 0.93
Interleukin-1beta activates specific populations of enteric neurons and enteric glia in the guinea pig ileum and colon. Am J Physiol Gastrointest Liver Physiol (2003) 0.92
Infection with an intestinal helminth parasite reduces Freund's complete adjuvant-induced monoarthritis in mice. Arthritis Rheum (2011) 0.91
Substrate-Selective Inhibition of Cyclooxygenase-2: Development and Evaluation of Achiral Profen Probes. ACS Med Chem Lett (2012) 0.91
Hyperdynamic circulation in portal-hypertensive rats is dependent on central c-fos gene expression. Hepatology (2002) 0.90
The neutral cannabinoid CB₁ receptor antagonist AM4113 regulates body weight through changes in energy intake in the rat. Pharmacol Biochem Behav (2010) 0.90
AM 251 produces sustained reductions in food intake and body weight that are resistant to tolerance and conditioned taste aversion. Br J Pharmacol (2006) 0.89
Distribution and function of monoacylglycerol lipase in the gastrointestinal tract. Am J Physiol Gastrointest Liver Physiol (2008) 0.89
Cytokines and irritable bowel syndrome: where do we stand? Cytokine (2011) 0.89
Neonatal immune challenge exacerbates experimental colitis in adult rats: potential role for TNF-alpha. Am J Physiol Regul Integr Comp Physiol (2006) 0.87
Antisecretory effects of neuropeptide Y in the mouse colon are region-specific and are lost in DSS-induced colitis. Regul Pept (2010) 0.86
Differential adipokine response in genetically predisposed lean and obese rats during inflammation: a role in modulating experimental colitis? Am J Physiol Gastrointest Liver Physiol (2009) 0.86
A role for O-1602 and G protein-coupled receptor GPR55 in the control of colonic motility in mice. Neuropharmacology (2013) 0.86
Expression of a functional metabotropic glutamate receptor 5 on enteric glia is altered in states of inflammation. Glia (2007) 0.86
The roles of purinergic signaling during gastrointestinal inflammation. Curr Opin Pharmacol (2012) 0.86
Oxidative stress disrupts purinergic neuromuscular transmission in the inflamed colon. J Physiol (2013) 0.85
Activation of proteinase-activated receptor-1 inhibits neurally evoked chloride secretion in the mouse colon in vitro. Am J Physiol Gastrointest Liver Physiol (2004) 0.84
Neuromuscular changes in a rat model of colitis. Auton Neurosci (2008) 0.84
Prion diseases and the gastrointestinal tract. Can J Gastroenterol (2006) 0.83
Proliferative capacity of enterochromaffin cells in guinea-pigs with experimental ileitis. Cell Tissue Res (2007) 0.83
Cannabinoid signalling regulates inflammation and energy balance: the importance of the brain-gut axis. Brain Behav Immun (2012) 0.82
Intestinal permeability and glucagon-like peptide-2 in children with autism: a controlled pilot study. J Autism Dev Disord (2008) 0.82
Endogenous prion protein attenuates experimentally induced colitis. Am J Pathol (2011) 0.82
Glucagon-like peptide 2 induces vasoactive intestinal polypeptide expression in enteric neurons via phophatidylinositol 3-kinase-γ signaling. Am J Physiol Endocrinol Metab (2012) 0.82
Cannabinoid 1 receptors are critical for the innate immune response to TLR4 stimulation. Am J Physiol Regul Integr Comp Physiol (2013) 0.80
Helminth parasites and the modulation of joint inflammation. J Parasitol Res (2011) 0.80
Urinary phenotyping indicates weight loss-independent metabolic effects of Roux-en-Y gastric bypass in mice. J Proteome Res (2013) 0.79
Peptide YY containing enteroendocrine cells and peripheral tissue sensitivity to PYY and PYY(3-36) are maintained in diet-induced obese and diet-resistant rats. Peptides (2007) 0.79
Interactive effects of oligofructose and obesity predisposition on gut hormones and microbiota in diet-induced obese rats. Obesity (Silver Spring) (2015) 0.79
Alterations to enteric neural signaling underlie secretory abnormalities of the ileum in experimental colitis in the guinea pig. Am J Physiol Gastrointest Liver Physiol (2009) 0.79
Cannabis and Δ9-tetrahydrocannabinol (THC) for weight loss? Med Hypotheses (2013) 0.78
Murine autoimmune arthritis is exaggerated by infection with the rat tapeworm, Hymenolepis diminuta. Int J Parasitol (2013) 0.78
Compromised neuroimmune status in rats with experimental colitis. J Physiol (2003) 0.78
Gastrointestinal viral load and enteroendocrine cell number are associated with altered survival in HIV-1 infected individuals. PLoS One (2013) 0.77
The subfornical organ: a novel site of action of cholecystokinin. Am J Physiol Regul Integr Comp Physiol (2014) 0.76
Neuropeptide y modulates L-type Ca2+ current during heart development. Circ Res (2003) 0.75
A unique therapeutic approach to emesis and itch with a proanthocyanidin-rich genonutrient. J Transl Med (2008) 0.75
Orally administered indomethacin acutely reduces cellular prion protein in the small intestine and modestly increases survival of mice exposed to infectious prions. Scand J Gastroenterol (2015) 0.75